Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6822701 | 0.85 | MAPK1 (0.32) | MAPK1KLKB1SMN1; SMN2L3MBTL1KDM4E | |
| Hydrochloric Acid SCHEMBL6825781 | 0.83 | MAPK1 (0.31) | MAPK1KLKB1 | |
| SCHEMBL30900609 | 0.74 | PIM3 (0.39) | MAPK1L3MBTL1KDM4E | |
| SCHEMBL23240415 | 0.69 | — | — | |
| SCHEMBL22275395 | 0.69 | SORD (0.31) | — | |
| SCHEMBL23240265 | 0.64 | — | — | |
| SCHEMBL6826099 | 0.63 | ADORA2A (0.43) | L3MBTL1KDM4E | |
| SCHEMBL30790727 | 0.60 | SMYD3 (0.40) | L3MBTL1KDM4E | |
| SCHEMBL10138649 | 0.60 | DHODH (0.32) | KDM4E | |
| SCHEMBL1088195 | 0.60 | MAPK1 (0.48) | MAPK1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007672-A1 | INHIBITORS OF MPTP | NRG THERAPEUTICS LTD (GB) | 2026-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007672-A1 | INHIBITORS OF MPTP | PARK7, SNCA, CYC1 | MAPK1 441/4885KLKB1 4649/4885SMN1; SMN2 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.